Literature DB >> 23492461

Outcomes of statin myopathy after statin withdrawal.

Ryan Armour1, Lan Zhou.   

Abstract

OBJECTIVE: To study the outcomes of statin myopathy after statin withdrawal.
METHODS: Sixty-nine patients with mild statin myopathy were studied by chart review.
RESULTS: Mean age at presentation was 62.1 years. Forty-nine (71.0%) of the 69 patients were men. Mean duration of follow-up after statin withdrawal was 18.2 months. Muscle symptoms improved in 9 (13.0%) and completely resolved in 50 (72.5%) patients. Thirteen (18.8%)/69 patients had symptoms lingered beyond 14 months. Creatine kinase (CK) levels were elevated in 52 (75.4%)/69 patients at initial presentation and returned to normal in 11 (21.3%)/52 patients at follow-up. Symptom improvement was not influenced by the initial presence of weakness, CK elevation, or myopathic changes on electromyography or muscle biopsy.
CONCLUSIONS: Muscle symptoms can linger beyond 14 months, and it is difficult to predict which patients will have a prolonged recovery course. CK normalization often lags behind symptom improvement, and this should not be the only indication for muscle biopsy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23492461     DOI: 10.1097/CND.0b013e3182852558

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  5 in total

1.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

Review 2.  Statin-Associated Muscle Adverse Events: Update for clinicians.

Authors:  Maha A Al-Mohaissen; Martha J Ignaszewski; Jiri Frohlich; Andrew P Ignaszewski
Journal:  Sultan Qaboos Univ Med J       Date:  2016-11-30

Review 3.  Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.

Authors:  Albert Selva-O'Callaghan; Marcelo Alvarado-Cardenas; Iago Pinal-Fernández; Ernesto Trallero-Araguás; José Cesar Milisenda; María Ángeles Martínez; Ana Marín; Moisés Labrador-Horrillo; Cándido Juárez; Josep María Grau-Junyent
Journal:  Expert Rev Clin Immunol       Date:  2018-02-23       Impact factor: 4.473

4.  Muscle rupture associated with statin use.

Authors:  Corine Ekhart; Loek de Jong; Liana Gross-Martirosyan; Florence van Hunsel
Journal:  Br J Clin Pharmacol       Date:  2016-05-18       Impact factor: 4.335

5.  Management of statin myopathy.

Authors:  Josef Finsterer; Marlies Frank
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-05-02       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.